Princeton Global Asset Management’s AbCellera Biologics ABCL Stock Holding History

Princeton Global Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.85K	Hold	1,000	–	–	﹤0.01%	614
2026 Q1	$3.49K	Hold	1,000	–	–	﹤0.01%	721
2025 Q4	$3.42K	Hold	1,000	–	–	﹤0.01%	715
2025 Q3	$5.03K	Buy	+1,000	New	+$4.41K	﹤0.01%	629

Other funds holding ABCL

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Pacifica Partners Surrey, Canada $332M AUM 59.28% 1-Year Est. Return

APW

Allied Private Wealth Boca Raton, Florida $156M AUM

Princeton Global Asset Management's ABCL Position: Q2 2026 in Review

Princeton Global Asset Management held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 1,000 shares worth $7.85K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Princeton Global Asset Management first reported a position in ABCL in Q3 2025 and has held it in 4 quarters since. 6 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Princeton Global Asset Management held 1,000 shares of AbCellera Biologics worth $7.85K as of Q2 2026.
Princeton Global Asset Management left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #614 holding.
Princeton Global Asset Management first reported a position in AbCellera Biologics in Q3 2025 and has held it in 4 quarters since.
6 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.